CClinicalTrials.gg
CompletedNCT04398212Updated Aug 10, 2020

Computer Vision Syndrome Visual Sequelae

An interventional study of mfERG (multifocal-retinogram) in Computer Vision Syndrome, sponsored by Sohag University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled May 2018, registered May 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
733
Allocation
Randomized
Sex
All
01

Study summary

the university students will respond to CVS-F3 survey form and then they will be subjected to complete ophthalmic examination and investigations

Read the detailed description

CVS-F3 is a survey form consisted of up to 30 questions regarding Computer Vision Syndrome (CVS) complains, thereafter a randomized sample of students will be subjected to complete ophthalmic examination including visual acuity and refractive measurements, intraocular pressure measurements, Slitlamp and fungus examinations, mfERG examinations. the sudents will be requested to decrease their screen time and the examinations will be repeated one month later.

02

Conditions studied

  • Computer Vision Syndrome

Browse trials for

03

In context

Syndrome

9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.

This study's enrollment of 733 is above the median of 50 across 6,515 interventional studies indexed under Syndrome.

Browse Syndrome studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • University students

Exclusion criteria

Exclusion Criteria:

  • Amblyopia
  • Anisometropia
  • strabismus
  • Previous eye surgery
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
733 participants (actual)

Study arms

  • Placebo comparator
    Non-complaining group

    the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it

    Diagnostic Test: mfERG (multifocal-retinogram)

  • Experimental
    Complaining group

    the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings

    Diagnostic Test: mfERG (multifocal-retinogram)

Interventions

  • Diagnostic testmfERG (multifocal-retinogram)

    mfERG will be performed for the students to document the effect of CVS on retina

06

What researchers measure

Primary outcomes

  1. visual acuity

    visual changes i.e. uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) using logMAR measurements following reduction of screen time

    Time frame: 1 month

  2. near vision

    near vision changes following reduction of screen hours using card test, near visual acuity chart and near point test while the measurements will be diopters and lines of near chart

    Time frame: 1 month

07

Study locations

1 site
  • Faculty of medicine
    Sohag, 82425, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04398212
Lead sponsor
Sohag University
Responsible party
Prof. Mohammed Iqbal (Assistant Professor of Ophthalmology, Sohag University) — Principal investigator
First posted
May 21, 2020
Start date
May 21, 2018
Primary completion
Jun 15, 2020
Completion
Aug 1, 2020
Last update
Aug 10, 2020

Study contacts

Mohammed Iqbal, MD. PhP
principal investigator · sohag university hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion